# US 2023/0364147 A1 · Method of targeting oncolytic viruses to tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0364147 A1
- Document ID: US20230364147A1
- Status: Published application
- Kind: A1
- Application number: 18/186,869
- Filed: 2023-03-20
- Published: 2023-11-16
- Earliest claimed: 2016-09-19
- Assignees: University of South Florida; The United States Government as represented by the Department of Veterans Affairs
- Applicants: University of South Florida; The United States Government AS Represented By the Department of Veterans Affairs
- Inventors: SHYAM S. MOHAPATRA; SUBHRA MOHAPATRA
- Web page: https://patentgrep.com/patent/US20230364147A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12N 5/0662: {Stem cells}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2510/00: Genetically modified cells
- C12N 2760/18532: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/18571: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention pertains to a strategy of selectively targeting oncolytic virotherapy, using either naturally occurring or genetically modified viruses by packaging them in mesenchymal stem cells (MSCs). The present invention concerns MSCs, compositions comprising the MSCs, and methods of using the MSCs for treatment of cancer and for lysing or inducing apoptosis of cancer cells in vitro or in vivo.

## Claims

### Claim 1

A mesenchymal stem cell (MSC) that over-expreses interferon-beta and is indoleamine 2,3-dioxygenase (IDO)-deficient.

### Claim 2 (depends on 1)

The MSC of claim 1, wherein the MSC is infected with a naturally occurring or genetically modified virus.

### Claim 3 (depends on 2)

The MSC of claim 2, wherein the virus is an oncolytic virus.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The MSC of claim 1, wherein the MSC is a human MSC.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A method for treating cancer, comprising administering an effective amount of the MSC of claim 1 to a human or non-human animal subject in need thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer is lung cancer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the lung cancer is non-small cell lung cancer (NSCLC).

### Claim 11 (depends on 8)

The method of claim 8, further comprising administering an inhibitor of indoleamine 2,3-dioxygenase (IDO inhibitor) to the subject.

### Claim at position 12

12-20. (canceled)

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the MSC of claim 1.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, further comprising an inhibitor of indoleamine 2,3-dioxygenase (IDO inhibitor).

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, further comprising an adjuvant.

### Claim 24 (depends on 1)

The MSC of claim 1, wherein the MSC is IDO-deficient due to deletion or gene silencing.

### Claim 25 (depends on 1)

The MSC of claim 1, wherein the MSC is IDO-deficient due to an IDO inhibitor.

### Claim 26 (depends on 25)

The MSC of claim 25, wherein the IDO inhibitor is selected from the group consisting of a tryptophan analog, a naphthoquinone based inhibitor, hydroxyamidine, an interfering RNA specific for IDO1 and/or IDO2, NLG919, and combinations thereof.
